Radiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1148/radiol.2383042164
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blake, M. A.
Right arrow Articles by Boland, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blake, M. A.
Right arrow Articles by Boland, G. W.
(Radiology 2006;238:970-977.)
© RSNA, 2006


Nuclear Medicine

Adrenal Lesions: Characterization with Fused PET/CT Image in Patients with Proved or Suspected Malignancy—Initial Experience1

Michael A. Blake, MRCPI, BSc, FRCR, FFR RCSI, James M. A. Slattery, MRCPI, FRCR, FFR RCSI, Mannudeep K. Kalra, MD, DNB, Elkan F. Halpern, PhD, Alan J. Fischman, MD, PhD, Peter R. Mueller, MD and Giles W. Boland, MD

1 From the Division of Abdominal and Interventional Radiology (M.A.B., J.M.A.S., M.K.K., P.R.M., G.W.B.) and Department of Nuclear Medicine (A.J.F.), White 270, Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114; and Institute for Technology Assessment, Boston, Mass (E.F.H.). Received December 21, 2004; revision requested February 22, 2005; revision received July 9; final version accepted August 2. Address correspondence to M.A.B.

Purpose: To retrospectively evaluate the accuracy of the fused positron emission tomographic (PET)/computed tomographic (CT) image for characterization of adrenal lesions in patients who have proved malignancy or are suspected of having malignancy.

Materials and Methods: Institutional review board approval was received for this retrospective HIPAA-compliant study, and informed consent was waived. Forty-one adrenal lesions in 38 patients (21 men, 17 women; mean age, 66 years; range, 37–86 years) were evaluated with PET/CT. Of the 41 lesions, nine were assumed to be malignant with documentation of enlargement (n = 8) or reduction in size in response to treatment (n = 1), and 32 were assumed to be benign with documentation of stability for 6 months (n = 31) or with confirmation with biopsy results (n = 1). The PET examination findings were positive when adrenal lesion maximum standardized uptake values (SUVs) exceeded hepatic maximum SUVs. CT contrast medium washout analysis was used to further characterize two lesions with PET findings positive for malignancy. The t test was used to assess significant (P < .05) differences between fluorine 18 fluorodeoxyglucose (FDG) uptake of benign lesions and that of malignant lesions.

Results: At PET/CT, findings for all malignant lesions were positive (mean adrenal lesion–liver activity ratio, 4.04; range, 1.53–17.08). Of the 32 benign lesions, most (30 of 32) had activity less than that of the liver (mean ratio, 0.66; range, 0.22–0.94). PET/CT demonstrated sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 100%, 93.8%, 81.8%, 100%, and 95.1%, respectively. Incorporating contrast material–enhanced CT with delayed imaging increased specificity to 100% because two lesions with PET findings positive for malignancy were characterized as benign. There was a significant difference between maximum SUV (P < .05) and the ratio of adrenal lesion–liver FDG activity (P < .001) in benign versus malignant adrenal lesions.

Conclusion: PET/CT provides a powerful combination of functional and attenuation information for adrenal lesion characterization. All malignant lesions were detected at PET/CT, with no false-negative results.

© RSNA, 2006




This article has been cited by other articles:


Home page
Am. J. Roentgenol.Home page
J. B. Roedl, R. R. Colen, K. King, A. J. Fischman, P. R. Mueller, and M. A. Blake
Visual PET/CT Scoring for Nonspecific 18F-FDG Uptake in the Differentiation of Early Malignant and Benign Esophageal Lesions
Am. J. Roentgenol., August 1, 2008; 191(2): 515 - 521.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
A. B. Elaini, S. K. Shetty, V. M. Chapman, D. V. Sahani, G. W. Boland, A. T. Sweeney, M. M. Maher, J. T. Slattery, P. R. Mueller, and M. A. Blake
Improved Detection and Characterization of Adrenal Disease with PET-CT
RadioGraphics, May 1, 2007; 27(3): 755 - 767.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
I. C. Mitchell and F. E. Nwariaku
Adrenal Masses in the Cancer Patient: Surveillance or Excision
Oncologist, February 1, 2007; 12(2): 168 - 174.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
S. Chong, K. S. Lee, H. Y. Kim, Y. K. Kim, B.-T. Kim, M. J. Chung, C. A Yi, and G. Y. Kwon
Integrated PET-CT for the Characterization of Adrenal Gland Lesions in Cancer Patients: Diagnostic Efficacy and Interpretation Pitfalls
RadioGraphics, November 1, 2006; 26(6): 1811 - 1824.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
RADIOLOGY RADIOGRAPHICS RSNA JOURNALS ONLINE
Copyright © 2006 by the Radiological Society of North America.